Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | EMI scheme | |||
| Period of return: | From: | 28 April 2022 | 27 October 2022 | |
| Balance of unallotted securities under scheme(s) from previous return: | 750,000 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 290,500 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 459,500 | |||
| Name of applicant: | Avacta Group plc | |||
| Name of scheme: | LTIP scheme | |||
| Period of return: | From: | 28 April 2022 | 27 October 2022 | |
| Balance of unallotted securities under scheme(s): | 1,250,000 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 790,813 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 459,187 | |||
| Name of contact: | Tony Gardiner, Company Secretary |
| Telephone number of contact: | + 44 (0) 1904 217070 |